A collection covering distinct plant-polyprenol preparations. Ropren from European spruce appears in the Russian POLYNCOR clinical program and a mouse demyelination study; Siberian-fir polyprenols appear in Shustov’s preclinical work. Botanical source, composition and administration differ. Marine extracts in the related research map are separate preparations.
Research background
A collection covering distinct plant-polyprenol preparations. Ropren from European spruce appears in the Russian POLYNCOR clinical program and a mouse demyelination study; Siberian-fir polyprenols appear in Shustov’s preclinical work. Botanical source, composition and administration differ. Marine extracts in the related research map are separate preparations.
Study of multiple preparations · Original preclinical journal publication
Animal findings do not establish human protection or clinical neuropathy benefit. The exact aminoethanol preparation is not sufficiently identified to equate it with ADK-17 or FDES. Group flow and agent-specific numerical outcomes require full text.
Study of this preparation · Clinical publication from NCT03122340
The reported 0 versus five (33.3%) statin changes do not establish the entire trial denominator. No mortality or cardiovascular-event benefit is established here. Industry affiliations appear among the authors; disclosures need full-text review. The 2021 report shares this program, not independent replication.
Study of this preparation · Conference abstract from the same POLYNCOR program
Participant flow must reconcile 70 registered versus 68 reported. No between-group differences were reported at discharge; later control values are absent. Not an independent trial or a general nootropic result.
These highlights cover selected studies. Open a source for its methods, reported doses and full context.
Compound class
Natural-product research collection
Research collection
Related nootropics & combinations · editorial grouping
Research institutions
No institutional affiliation recorded
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH
Understanding the evidence
Human research
One identified POLYNCOR program with multiple reports; related preparations are not interchangeable
Study methods
Registered placebo-controlled adjunctive clinical research; animal toxicology and demyelination experiments
Independent replication
The 2018 and 2021 POLYNCOR reports belong to one trial program; external replication is unresolved
Source access
Registry JSON, indexed and publisher-deposited abstracts, and a complete original open-access XML article; see each record
Safety evidence
Limited preparation-specific observations; no class-wide safety or human MS-treatment conclusion
Open a topic for the evidence assessment.
More findings, background and historyEVIDENCE REVIEW / 6 OCTOBER 2026
Outstanding review questions
Check full allocation, comparator, prespecified outcomes, effect estimates, harms and shared-cohort reporting before drawing a clinical conclusion.
Human reports are linked; their presence does not establish effectiveness. Publication records can share participants. Source counts are not trial counts.
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
1999 · RU2137479C1 · Polyprenols: immunomodulatory class-use patentUse · Stimulation occurred under some conditions and suppression under others
1999 · Polyprenols: immunomodulatory class-use patent — RU2137479C1Context-dependent immune response: Stimulation occurred under some conditions and suppression under others
1999Patent / reported experimentsFull text available
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
В.И. Рощин · RU2137479C1 · patent family 20196666
The direction of immune effects depended on genotype, exposure and assay; the patent does not support a uniformly stimulatory class effect.
The direction of immune effects depended on genotype, exposure and assay; the patent does not support a uniformly stimulatory class effect.
Conifer-derived polyprenol immune-response experiments in animals, including stress-associated immune suppression.
Reported findings and study figures · Final immune-response and stress-model conclusions.
Measure
Result
Comparison, timing and statistics
Context-dependent immune response
Stimulation occurred under some conditions and suppression under others
No single pooled clinical immune-effect size established
Stress-associated findings
Prevention of the reported humoral and macrophage-function impairment described
Animal model; not a patient autoimmune outcome
These class-level animal findings cannot authenticate or establish efficacy of every Ropren/POLYNCOR formulation, and immune stimulation is not automatically beneficial in autoimmune disease.
Conifer-derived polyprenol immune-response experiments in animals, including stress-associated immune suppression.
What was checked
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Limitations & review scope
A chemical-class patent does not authenticate every Ropren or POLYNCOR product, nor demonstrate each product's clinical effect.
These class-level animal findings cannot authenticate or establish efficacy of every Ropren/POLYNCOR formulation, and immune stimulation is not automatically beneficial in autoimmune disease.
Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Source checked 2026-11-06. See the review scope above for the material assessed.
Read the source ↗2026 · Potapov–Shustov: pharmacological correction of delayed neuropathy in ratsAminoethanol derivative and citicoline: Favorable responses depended on the experimental model.
2026Animal / experimentalRussian source · see review scope
Aminoethanol and inositol derivatives, polyprenols, citicoline and Cortexin comparators · Original preclinical journal publication
Format: Original publisher abstract and references · Reviewed: Abstract, authors and citation trail checked; full tables not recovered
P. K. Potapov, E. B. Shustov, V. Ya. Apchel, A. N. Smirnov, A. S. Melekhova, M. V. Melnikova, V. A. Basharin, A. A. Bondarenko · Bulletin of the Russian Military Medical Academy. 2026;28(1):33–44
Responses at approximately one month varied by model; an inositol derivative worsened selected neuromuscular findings in some animals.
Findings, study figures and available tables
Reported findings and study design
Rat experiment with day-30 neuromuscular measurements; compound identities and group denominators need full-paper confirmation.
Reported findings and study figures · Original publisher abstract; qualitative findings only
Measure
Result
Comparison, timing and statistics
Aminoethanol derivative and citicoline
Favorable responses depended on the experimental model.
Unfavorable response
An inositol derivative worsened selected neuromuscular findings in some animals.
Not every tested agent showed benefit. No human efficacy estimate or equivalence with ADK-17/FDES established.
Original abstract; no quantitative treatment effect extracted.
Limitations & review scope
Animal findings do not establish human protection or clinical neuropathy benefit.
The exact aminoethanol preparation is not sufficiently identified to equate it with ADK-17 or FDES.
Group flow and agent-specific numerical outcomes require full text.
Source checked 2026-11-06. See the review scope above for the material assessed.
Read the source ↗2018 · POLYNCOR: lipid and liver-enzyme findings with adjunctive RoprenStatin reduction/discontinuation for raised transaminases: Ropren: zero (0%); control: five (33.3%); reported p<0.05.
68 patients with acute coronary syndrome; 34 per group
What was checked
Original abstract; registry separately reports actual enrollment of 70.
Limitations & review scope
Participant flow must reconcile 70 registered versus 68 reported.
No between-group differences were reported at discharge; later control values are absent.
Not an independent trial or a general nootropic result.
Source checked 2026-11-06. See the review scope above for the material assessed.
Read the source ↗2019 · Spruce polyprenols in a mouse demyelination modelAnimals and histology: 27 allocated, nine per group; histology examined seven per group.
Picea abies polyprenols supplied as Ropren; injected experimental preparation · Original preclinical research; Shustov is not an author
Format: Complete original open-access XML recovered through Europe PMC · Reviewed: Methods, results narrative and stated limitations checked; graph values not visually transcribed
M. Y. Khodanovich, A. O. Pishchelko, V. Y. Glazacheva, E. S. Pan, E. P. Krutenkova, V. B. Trusov, V. L. Yarnykh · Phytotherapy Research. 33(5):1363–1373
The authors reported greater myelin-marker signal and altered cell-marker patterns in treated mice compared with toxin-exposed vehicle controls.
Findings, study figures and available tables
Reported findings and study design
Reported findings and study figures · Original full-text XML, methods and results narrative; no graph-digitized effect sizes
Measure
Result
Comparison, timing and statistics
Animals and histology
27 allocated, nine per group; histology examined seven per group.
Myelin and cell markers
The treated group had greater myelin-basic-protein signal than the toxin-exposed vehicle group; selected precursor-cell and immature-neuron markers also differed.
The design does not isolate remyelination from protection against continued injury, and it is not a human MS treatment study.
Laboratory animals in a chronic toxic-exposure model; sample size absent from the checked abstract
What was checked
Publisher-deposited abstract; no human result.
Limitations & review scope
Raw outcomes, group sizes and allocation are not supplied in the reviewed abstract.
The English abstract uses polyphenols in one sentence despite the title and context saying polyprenols; check the original preparation.
Biochemical changes do not establish human cognitive or autoimmune benefit.
Source checked 2026-11-06. See the review scope above for the material assessed.
Read the source ↗2024 · Siberian-fir polyprenols under combined adverse exposuresReported preclinical responses: Antioxidant, anabolic and hematopoietic activity was described.
Polyprenols from Abies sibirica needles · Original preclinical report; same source as the existing shustov-polyprenols-2024 bibliography lead
Format: Publisher-deposited Crossref abstract and indexed original first-page metadata · Reviewed: Abstract and metadata checked; complete PDF not recovered
M. V. Melnikova, E. B. Shustov, E. A. Zolotoverkhaya, L. G. Kubarskaya, A. A. Bondarenko, A. V. Belskaya, A. A. Vataeva · Journal Biomed. 20(3):89–93
Antioxidant, anabolic and hematopoietic activity is reported in an experimental combined-exposure setting.
Findings, study figures and available tables
Reported findings and study design
Reported findings and study figures · Publisher-deposited or original indexed abstract; qualitative extraction
Measure
Result
Comparison, timing and statistics
Reported preclinical responses
Antioxidant, anabolic and hematopoietic activity was described.
Qualitative report of the same 2024 publication already present as an archival lead; not an independent replication or human result.